# Safety and Clinical Tolerability of hdmASIT+TM Peptides Administered in HDM-induced Allergic Patients

> **NCT03094845** · PHASE2 · COMPLETED · sponsor: **ASIT Biotech S.A.** · enrollment: 36 (actual)

## Conditions studied

- House Dust Mite Allergy

## Interventions

- **BIOLOGICAL:** Placebo solution
- **BIOLOGICAL:** hdmASIT+TM

## Key facts

- **NCT ID:** NCT03094845
- **Lead sponsor:** ASIT Biotech S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-28
- **Primary completion:** 2017-01-12
- **Final completion:** 2017-01-23
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03094845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03094845, "Safety and Clinical Tolerability of hdmASIT+TM Peptides Administered in HDM-induced Allergic Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03094845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*